

III REUNIÓN DEL GRUPO DE PULMÓN

De Oncología Radioterápica de Madrid

Grupo
Cáncer de Pulmón
MADRID

SEDE: AULA SEVERO OCHOA (FUNDACIÓN JIMÉNEZ DÍAZ)

Moderadores: Dr. Felipe Couñago y Dr. Javier Luna

16:30H. APERTURA

16:40H. MESA 1: DRA. SUSANA GONZALO. H. UNIVERSITARIO LA PRINCESA

PACIFIC: PACIFIC: 5-Year Survival Outcomes With Consolidation Durvalumab vs Placebo After Concurrent CRT in Unresectable Stage III NSCLC.

PACIFIC-R: real-world characteristics of unresectable Stage III NSCLC patients treated with durvalumab after chemoradiotherapy.

S-REAL: Características de los pacientes con CPNM estadio III irresecable tratados con Durvalumab tras Quimiorradioterapia dentro del Programa de Medicamentos de Uso Especial en España PACIFIC.

16:55H. MESA 2: DRA. SARA PEDRAZA. H. UNIVERSITARIO 12 DE OCTUBRE

The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KE-AP1-NFE2L2-Mutant Tumors.

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.

17:10H. DISCUSIÓN MESA 1 Y 2

17:30H. MESA 3: DR. RAÚL HERNANZ. H. UNIVERSITARIO RAMÓN Y CAJAL

Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6).

A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST).

17:45H. MESA 4: DRA. MARIAN GÓMEZ APARICIO. H. UNIVERSITARIO DE TOLEDO

Stereotactic ablative radiotherapy in operable stage I NSCLC patients: Long-term results of the expanded STARS clinical trial Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Non-randomized Trial.

MADRID. 28 DE MARZO
2022

18:00H. DISCUSIÓN MESA 3 Y 4

**18:20H. MESA 5: DRA. MARINA SANTOS.
H. UNIVERSITARIO GREGORIO MARAÑÓN
NOVEDADES ASTRO 2021**

A randomised phase 2 trial of nivolumab and SBRT in advanced NSCLC, progressing after first or second line chemotherapy (NIVORAD).

Mature outcomes of 61,2 Gy Concomitant Boost Thoracic Radiotherapy in Limited Stage small cell lung cancer LSSCLC: CALGB 30610 Alliance/RTOG 0538.

A phase 2 trial of primary tumor SBRT Boost prior to concurrent chemoradiation for locally-Advanced Non Small Cell Lung Cancer (LA NSCLC).

Cardiac Radiation Dose and Patient risk factors for predicting major adverse cardiac events in lung cancer patients.

Stereotactic Body Radiotherapy (SBRT) with Biologically Equivalent Dose>150Gy is Associated with improved local control in patients with Squamous but not Non-Squamous Cell Carcinoma of the Lung: A Multi-Institutional Analysis.

Targeted high-dose radiation therapy led to a fivefold improvement in progression-free survival (PFS) for patients with oligoprogressive lung cancer.

The potential for individualised stereotactic ablative radiotherapy (SABR) dosing to treat lung tumours.

18:40H. DISCUSIÓN ASTRO

19:00H. CIERRE

ORGANIZAN: **Grupo
Cáncer de Pulmón
MADRID**

Aedc
Asociación Española de
Divulgación Científica

COLABORA:

AstraZeneca

SEC. TÉCNICA:

EMIRAL

Grupo Cáncer de Pulmón MADRID

SEDE: AULA SEVERO OCHOA
(FUNDACIÓN JIMÉNEZ DÍAZ)